anti-HER3 antibody-drug conjugate YL202

{
  "id": "MLC-T-ONC-010774",
  "term": "anti-HER3 antibody-drug conjugate YL202",
  "field": "Oncology and biomedicine",
  "definition": "An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against human epidermal growth factor receptor 3 (HER3; ErbB3) conjugated via a tumor microenvironment (TME) activable protease-cleavable linker to a cytotoxic DNA topoisomerase I inhibitor, with potential antineoplastic activity. Upon administration of anti-HER3 ADC YL202, the anti-HER3 antibody moiety targets and binds to HER3 expressed on tumor cells. Upon proteolytic cleavage in the TME and the release of the topoisomerase I inhibitor, the topoisomerase I inhibitor targets and binds to DNA topoisomerase I, thereby stabilizing the cleavable complex between topoisomerase I and DNA and resulting in DNA breaks, inhibition of DNA replication and apoptosis in HER3-expressing tumor cells. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors.",
  "synonyms": [
    "anti-HER3 ADC YL202",
    "YL202",
    "HER3-targeting antibody-drug conjugate YL202"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-her3-antibody-drug-conjugate-yl202/"
}